PMID- 8252476
OWN - NLM
STAT- MEDLINE
DCOM- 19940113
LR  - 20190620
IS  - 0008-543X (Print)
IS  - 0008-543X (Linking)
VI  - 72
IP  - 12
DP  - 1993 Dec 15
TI  - Successful treatment of a patient with adult T-cell leukemia by daily oral 
      administration of low-dose etoposide. Decrease in the amount of HTLV-I proviral 
      DNA revealed by the polymerase chain reaction method.
PG  - 3614-7
AB  - BACKGROUND: Oral administration of low-dose etoposide is known to be effective 
      against various malignancies, including malignant lymphoma. However, the 
      effectiveness of low-dose etoposide as a treatment for adult T-cell leukemia 
      (ATL) has not been established. METHODS: A 74-year-old woman with ATL in acute 
      phase was treated by daily oral administration of low-dose etoposide (25 mg/m2). 
      The authors assayed changes in the surface markers and the amount of human T-cell 
      lymphotropic virus type I (HTLV-I) proviral DNA in peripheral blood mononuclear 
      cells (PBMC) by using flow cytometry and the polymerase chain reaction (PCR) 
      method, respectively. RESULTS: Before treatment, generalized lymphadenopathy and 
      hepatomegaly were observed. In laboratory examination, the leukocyte count was 
      13.7 x 10(3)/microliters, with 65% abnormal lymphocytes. The percentages of CD3-, 
      CD4-, and CD25-positive cells in PBMC were 84.4%, 84.4%, and 76.5%, respectively. 
      The serum lactic dehydrogenase (LDH) level was 1376 IU/l (normal range, less than 
      520 IU/l). After the initiation of treatment, lymph-adenopathy and hepatomegaly 
      disappeared, and the serum LDH level was reduced to the normal level before the 
      20th day of the treatment. On the 55th day of the treatment, CD25-positive cells 
      had virtually disappeared. In addition, the amount of the proviral DNA in PBMC 
      was reduced to approximately one-tenth by this treatment. Subsequently, the 
      patient was in remission for more than 16 months. No side effects were observed. 
      CONCLUSIONS: Daily oral administration of low-dose etoposide can be a safe and 
      effective treatment for patients with ATL. The authors believe this to be the 
      first report of a patient with ATL in whom complete remission (CR) was achieved 
      by this treatment.
FAU - Kojima, H
AU  - Kojima H
AD  - Division of Hematology, University of Tsukuba, Ibaraki, Japan.
FAU - Hori, M
AU  - Hori M
FAU - Shibuya, A
AU  - Shibuya A
FAU - Nagasawa, T
AU  - Nagasawa T
FAU - Miwa, M
AU  - Miwa M
FAU - Abe, T
AU  - Abe T
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Cancer
JT  - Cancer
JID - 0374236
RN  - 0 (DNA, Viral)
RN  - 6PLQ3CP4P3 (Etoposide)
SB  - IM
MH  - Administration, Oral
MH  - Aged
MH  - Base Sequence
MH  - DNA, Viral/*analysis
MH  - Etoposide/administration & dosage/*therapeutic use
MH  - Female
MH  - Human T-lymphotropic virus 1/*genetics
MH  - Humans
MH  - Leukemia, T-Cell/*drug therapy/microbiology
MH  - Molecular Sequence Data
MH  - Polymerase Chain Reaction
MH  - Proviruses/*genetics
EDAT- 1993/12/15 00:00
MHDA- 1993/12/15 00:01
CRDT- 1993/12/15 00:00
PHST- 1993/12/15 00:00 [pubmed]
PHST- 1993/12/15 00:01 [medline]
PHST- 1993/12/15 00:00 [entrez]
AID - 10.1002/1097-0142(19931215)72:12<3614::aid-cncr2820721211>3.0.co;2-e [doi]
PST - ppublish
SO  - Cancer. 1993 Dec 15;72(12):3614-7. doi: 
      10.1002/1097-0142(19931215)72:12<3614::aid-cncr2820721211>3.0.co;2-e.